4 September 2019 - NICE has recommended the NHS should fund Novartis’ Luxturna for a rare eye disorder, after the company agreed a discount from the list price of more than £613,000 per patient.

Luxturna (voretigene neparvovec) is approved for use in people with vision loss caused by inherited retinal dystrophy from confirmed RPE65 gene mutations, and NICE has okayed funding in those who have enough retinal cells.

The first licensed therapy for the inherited disease, NICE has fast-tracked its review of Luxturna, taking 20 weeks instead of the average 38 weeks within the Highly Specialised Technologies programme.

Read Pharmaphorum article